Iceland· IS-EU/1/18/1322/001-002
Imfinzi
A durvalumab product containing durvalumabum inn, registered in Iceland by AstraZeneca AB. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Durvalumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF03 (durvalumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Durvalumab · ATC L01FF03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of durvalumab costs, country by country.
Normalised to the WHO defined daily dose (53.6 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Durvalumab · price per daily dose (53.6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$274.31
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Durvalumabum INN
- Manufacturer
- AstraZeneca AB
- Country
- Iceland (IS)
- ATC code
- L01FF03
- ATC class
- Durvalumab
- Defined daily dose
- 53.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 2
2 priced- ean05921110 ml x1 hglISK 463628
- ean5021572,4 ml x1 hglISK 116068
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for durvalumab.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Durvalumab · interactions on record
82 records
- 30 severe
- 45 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Durvalumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandImfinzi2care4 ApS
- CzechiaIMFINZIAstraZeneca AB, Södertälje
- BelgiumImfinzi 50 mg/mlAstraZeneca
- SwedenImfinzi 50 mg/ml Koncentrat till infusionsvätska, lösningAstraZeneca AB
- IrelandIMFINZI 50 mg/ml concentrate for solution for infusion.AstraZeneca AB
- NorwayImfinziAstraZeneca AB (2)
- PolandImfinziAstraZeneca AB
- United StatesIMFINZIAstraZeneca Pharmaceuticals LP
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Imfinzi
- Norway · Imfinzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7b39e15c-73ca-47b6-a7fe-e1d7d236d530 GET /v1/drugs/7b39e15c-73ca-47b6-a7fe-e1d7d236d530?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FF03",
"marketed": true,
"strength": "50 mg/ml",
"ma_number": "EU/1/18/1322/001-002",
"substance": "Durvalumabum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "43364"
}See everything about durvalumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.